Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Non-Current Assets (2016 - 2026)

Myriad Genetics has reported Non-Current Assets over the past 16 years, most recently at $374.0 million for Q4 2025.

  • Quarterly Non-Current Assets fell 48.74% to $374.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 billion through Dec 2025, down 40.31% year-over-year, with the annual reading at $374.0 million for FY2025, 48.74% down from the prior year.
  • Non-Current Assets was $374.0 million for Q4 2025 at Myriad Genetics, down from $383.3 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $1.0 billion in Q1 2021 and troughed at $374.0 million in Q4 2025.
  • The 5-year median for Non-Current Assets is $830.4 million (2022), against an average of $773.7 million.
  • Year-over-year, Non-Current Assets rose 10.55% in 2022 and then crashed 51.36% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $835.9 million in 2021, then rose by 10.55% to $924.1 million in 2022, then dropped by 9.87% to $832.9 million in 2023, then fell by 12.4% to $729.6 million in 2024, then crashed by 48.74% to $374.0 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Non-Current Assets are $374.0 million (Q4 2025), $383.3 million (Q3 2025), and $393.0 million (Q2 2025).